Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04385966
Other study ID # REDOLEV-2019
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date February 11, 2020
Est. completion date October 20, 2021

Study information

Verified date August 2021
Source Instituto de Investigación Sanitaria Aragón
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Arthroscopic shoulder surgery involves dynamic and severe postoperative pain. Interscalene brachial plexus block (IBPB) provides adequate analgesia but the spread of local anaesthetics administered causes a phrenic nerve block which entrains a non-negligible incidence of Hemidiaphragmatic paralysis acute (HDPA). This is a comparative, prospective, Unicenter, double-blind, two-arm, randomized and controlled clinical trial. 48 patients will be included. This RCT would demonstrate a low volume dose IBPB decrease the HDPA after IBPB in patients undergoing SAS, by using spirometry and ultrasound and it will not provide inferior postoperative analgesia according to opioid requirements of postoperative PCA in comparison to standard volume dose used in current practice.


Description:

Arthroscopic shoulder surgery involves dynamic and severe postoperative pain. Interscalene brachial plexus block (IBPB) provides adequate analgesia but the spread of local anaesthetics administered causes a phrenic nerve block which entrains a non-negligible incidence of Hemidiaphragmatic paralysis acute (HDPA). The primary study objective is to determine the HDPA diagnosed by using diaphragmatic thickness index in Ultrasound (US) after Low Volume (10 mL) versus Standard Volume (20 mL) of Levobupivacaine 0,25% for IBPB. Secondary end-points are 1) HDPA diagnosed by using FVC and FEV1 in spirometry, 2) HDPA diagnosed by using diaphragmatic excursion in US, 3) postoperative pain regarding time to first analgesic consumption and 24-hour cumulative total consumption of Patient-controlled analgesia (PCA) pump of Morphine IV and (4) postoperative harms between two trial-arms. This study is a comparative, prospective, Unicenter, double-blind and two-arm RCT. 48 patients will be included. This RCT would demonstrate a low volume dose IBPB decrease the HDPA after IBPB in patients undergoing SAS, by using spirometry and ultrasound and it will not provide inferior postoperative analgesia according to opioid requirements of postoperative PCA in comparison to standard volume dose used in current practice.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date October 20, 2021
Est. primary completion date October 20, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients aged 18 to 80 years. - ASA I-III. - Scheduled for shoulder arthroscopic shoulder surgery and interscalene brachial plexus block. Exclusion Criteria: - Age <18 and >80 years. - Pregnancy. - Exclusión to perform IBPB or spirometry. - Allergy to amide group local anaesthetics, opioids or nonsteroidal anti-inflammatory drugs. - Background of Pulmonary diseases (chronic obstructive pulmonary disease (COPD) and moderate, severe or not well-controlled asthma), diaphragmatic paralysis or neurological disease with diaphragmatic dysfunction, brachial plexus neuropathy or chronic opioid consumption (more than 3-months consumption or more than oral Morphine 1 mg 1-month). - Coagulation disorders (INR>3, TTPA > 35 y AP <50%).

Study Design


Intervention

Procedure:
Interscalene brachial plexus block
Interscalene brachial plexus block is a locorregional anaesthesia technique which is indicated in shoulder and upper arm surgery. The goal of this block is to place the needle in the tissue space between the anterior and middle scalene muscles and inject local anesthetic until the spread around the brachial plexus is documented by ultrasound.
Drug:
Levobupivacaine Hydrochloride 2.5 MG/ML
Levobupivacaine Hydrochloride 2.5 MG/ML is an anesthestic product intended for epidural, intradural and perineural administration. Levobupivacaine is chemically described as (S)-l-butyl-2-piperidylformo-2',6'-xylidide hydrochloride. It is a white crystalline powder with a molecular formula of C18H28N2O. HCl, with a molecular weight 324.9. FDA approval: NDA-20997 (1999).

Locations

Country Name City State
Spain Hospital Universitario Miguel Servet Zaragoza

Sponsors (2)

Lead Sponsor Collaborator
Instituto de Investigación Sanitaria Aragón Hospital Miguel Servet

Country where clinical trial is conducted

Spain, 

References & Publications (5)

López Escárraga VM, Dubos España K, Castillo Bustos RH, Peidró L, Sastre S, Sala-Blanch X. Diaphragmatic thickness ratio (inspiratory/expiratory) as a diagnostic method of diaphragmatic palsy associated with interescalene block. Rev Esp Anestesiol Reanim (Engl Ed). 2018 Feb;65(2):81-89. doi: 10.1016/j.redar.2017.09.008. Epub 2017 Nov 7. English, Spanish. — View Citation

Stundner O, Meissnitzer M, Brummett CM, Moser S, Forstner R, Koköfer A, Danninger T, Gerner P, Kirchmair L, Fritsch G. Comparison of tissue distribution, phrenic nerve involvement, and epidural spread in standard- vs low-volume ultrasound-guided interscalene plexus block using contrast magnetic resonance imaging: a randomized, controlled trial. Br J Anaesth. 2016 Mar;116(3):405-12. doi: 10.1093/bja/aev550. — View Citation

Thackeray EM, Swenson JD, Gertsch MC, Phillips KM, Steele JW, Burks RT, Tashjian RZ, Greis PE. Diaphragm function after interscalene brachial plexus block: a double-blind, randomized comparison of 0.25% and 0.125% bupivacaine. J Shoulder Elbow Surg. 2013 Mar;22(3):381-6. doi: 10.1016/j.jse.2012.06.011. Epub 2012 Sep 1. — View Citation

Urmey WF, McDonald M. Hemidiaphragmatic paresis during interscalene brachial plexus block: effects on pulmonary function and chest wall mechanics. Anesth Analg. 1992 Mar;74(3):352-7. — View Citation

Urmey WF, Talts KH, Sharrock NE. One hundred percent incidence of hemidiaphragmatic paresis associated with interscalene brachial plexus anesthesia as diagnosed by ultrasonography. Anesth Analg. 1991 Apr;72(4):498-503. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline Diaphragmatic Thickness Ratio at 4 hours The primary outcome is the difference in the proportion of patients with Hemidiaphragmatic paralysis acute (HDPA) according to diaphragmatic thickness ratio (DTR) in ultrasounds between the Treatment and Control groups. DTR will be the result of Inspiratory Diaphragmatic Thickness and Expiratory Diaphragmatic Thickness. The ratio will be defined by DTR=IDT/EDT. HDPA after IBPB at 4 hours will be diagnosed with a DTR<1.2. Before (Baseline) and 4-hour after interscalene brachial plexus block
Secondary Change from Baseline FVC at 4 hours and 24 hours This secondary outcome is the difference in the proportion of patients with Hemidiaphragmatic paralysis acute (HDPA) according to Forced Vital Capacity (FVC) in spirometry. HDPA will be diagnosed with a CVF diminution of >20%. Before (Baseline), 4-hour and 24-hour after interscalene brachial plexus block
Secondary Change from Baseline FEV1 at 4 hours and 24 hours This secondary outcome is the difference in the proportion of patients with Hemidiaphragmatic paralysis acute (HDPA) according to forced expiratory volume in one second (FEV1) in spirometry. HDPA will be diagnosed with a FEV1 diminution of >20%. Before (Baseline), 4-hour and 24-hour after interscalene brachial plexus block
Secondary Change from Baseline Diaphragmatic excursion at 4 hours and 24 hours This secondary outcome is the difference in the proportion of patients with Hemidiaphragmatic paralysis acute (HDPA) according to Diaphragmatic excursion expressed as number of intercostal spaces and motion type. HDPA will be diagnosed with a reduction of >25% number of intercostal spaces or a paradoxal or nule diaphragmatic motion. Before (Baseline), 4-hour and 24-hour after interscalene brachial plexus block
Secondary Postoperative IV morphine consumption This secondary outcome is the postoperative 24-hour cumulative IV morphine consumption (mg) of Patient controlled analgesia (PCA) pump. From 4-hour to 24-hour after interscalene brachial plexus block
Secondary Postoperative time to first analgesic consumption This secondary outcome is the time to first analgesic consumption (minutes) of Patient controlled analgesia (PCA) pump. From 4-hour to 24-hour after interscalene brachial plexus block
Secondary Incidence and frequency of Serious Adverse Events (SAE) This secondary outcome is the incidence, frequency and severity of Serious Adverse Events (SAE) as assessed by CTCAE v4.0 in the two study groups From performing the interscalene brachial plexus block to finish the 24-hour postoperative follow-up
See also
  Status Clinical Trial Phase
Withdrawn NCT04053491 - Comparison of the Infraclavicular and Axillary Approaches for Continuous Ultrasound-guided Brachial Plexus Block. N/A
Completed NCT03211949 - Ultrasound Guided Topographic Mapping of Medial Antebrachial Cutaneous Nerve N/A
Suspended NCT03291691 - Protective Nerve Stimulation in Regional Anesthesia
Completed NCT03270033 - Intravenous Dexmedetomidine, Dexamethasone and Interscalene Block Duration After Arthroscopic Shoulder Surgery Phase 4
Recruiting NCT06015204 - Assessment of the C8 Dermatomal Block With Photoplethysmographic Amplitude After Interscalene Brachial Plexus Block N/A
Not yet recruiting NCT03279679 - Comparison Between Costoclavicular and Paracoracoid Ultrasound-guided Infraclavicular Block for Forearm Surgery N/A
Completed NCT02305875 - The Musculocutaneous Nerve in a High Resolution MRI N/A
Completed NCT03688724 - Perioperative Diaphragm Point of Care Ultrasound
Completed NCT05005260 - Liposomal Bupivacaine Single-Injection Interscalene Block vs. Continuous Interscalene Block for Primary Total Shoulder Arthroplasty Phase 4
Completed NCT02312453 - Posterior Parasagittal In-Plane Ultrasound-Guided Infraclavicular Brachial Plexus Block N/A
Completed NCT02462408 - Conventional Versus Posterior Approach in Ultrasound-Guided Parasagittal In-Plane Infraclavicular Brachial Plexus Block N/A
Completed NCT00321425 - Ultrasound Guidance Vs. Electrical Nerve Stimulation for Infraclavicular Brachial Plexus Block N/A
Recruiting NCT03577860 - Ventilation and Pulmonary Aeration, Electrical Impedance Tomography, Interscalene Brachial Plexus Block N/A
Completed NCT04356521 - Lateral Sagittal vs Costoclavicular Approach for Ultrasound-Guided Infraclavicular Block N/A
Completed NCT04463329 - Jedi Grip vs. Double Operator Technique for Axillary Brachial Plexus Block N/A
Not yet recruiting NCT04784104 - Comparison of Infraclavicular And Supraclavicular Block Phase 4
Terminated NCT03785392 - Out of Plane Approach for Interscalene N/A
Completed NCT02787018 - Dexamethasone Compared With Dexmedetomidine as an Adjuvant to Ropivacaine for Supraclavicular Brachial Plexus Block Phase 3
Completed NCT03514342 - The Effects of Horner's Syndrome Developing After Interscalene Brachial Plexus Block on Autonomic Nervous Activity
Completed NCT05315271 - Supraclavicular Brachial Plexus Block During Upper Limb Surgeries Early Phase 1